EDAP TMS S.A. Reports Record Q2 2024 Revenue

TL;DR

EDAP TMS S.A. CRUSHED Q2 REVENUE, HIT RECORD HIGHS!

AI Summary

EDAP TMS S.A. reported record second quarter 2024 revenue of EUR 15.8 million (USD 17.0 million), a 10.6% increase compared to Q2 2023. For the first half of 2024, total worldwide revenue reached a record EUR 30.7 million (USD 33.1 million). The report was filed on August 28, 2024, with Ken Mobek, Chief Financial Officer, signing on behalf of the company.

Why It Matters

This filing indicates strong financial performance for EDAP TMS S.A., suggesting potential growth and market acceptance of their products.

Risk Assessment

Risk Level: low — The filing is a routine financial results report and does not contain significant new risks or negative developments.

Key Numbers

• EUR 15.8M — Q2 2024 Revenue (Record revenue for the second quarter of 2024.)
• 10.6% — Q2 Revenue Growth (Year-over-year percentage increase in Q2 revenue.)
• EUR 30.7M — H1 2024 Revenue (Record revenue for the first half of 2024.)

Key Players & Entities

• EDAP TMS S.A. (company) — Filing company
• EUR 15.8 million (dollar_amount) — Q2 2024 revenue
• USD 17.0 million (dollar_amount) — Q2 2024 revenue in USD
• EUR 30.7 million (dollar_amount) — First half 2024 revenue
• USD 33.1 million (dollar_amount) — First half 2024 revenue in USD
• August 28, 2024 (date) — Filing date
• Ken Mobek (person) — Chief Financial Officer

FAQ

Key Financial Figures

• $15 billion — ity and debt transactions, raising over $15 billion in aggregate. · On August 6, 2

Filing Documents

• f6k_082824.htm (6-K) — 184KB
• logo.jpg (GRAPHIC) — 2KB
• 0001171843-24-004952.txt ( ) — 188KB

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: August 28, 2024 EDAP TMS S.A. /s/ KEN MOBECK KEN MOBECK CHIEF FINANCIAL OFFICER EDAP Reports Second Quarter 2024 Financial Results - Record Q2 2024 total worldwide revenue of EUR 15.8 million (USD 17.0 million) increased 10.6% over Q2 2023 - Record first half 2024 total worldwide revenue of EUR 30.7 million (USD 33.1 million) increased 5.6% over first half 2023 - Strong Q2 2024 U.S. Focal One ® HIFU procedure growth of +63% year-over-year - Company to host conference call and webcast today, August 28th, at 8:30 a.m. EDT LYON, France, August 28, 2024 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, reported today unaudited consolidated financial results for the second quarter of 2024. “We continue to see growing demand for our proprietary and leading Focal One robotic HIFU technology platform. In the second quarter, we placed five Focal One systems, which included placements with two additional National Cancer Institute (NCI) designated comprehensive cancer centers. A growing number of top tier cancer research and treatment centers continue to adopt Focal One to help patients manage their prostate cancer, which reflects the innovation and positive clinical outcomes of our leading robotic HIFU platform,” said Ryan Rhodes, Chief Executive Officer of EDAP TMS. “We also experienced strong year over year procedure growth, which points towards the growing adoption of robotic HIFU amongst urologists across both academic and community hospitals. “There is also an increasing body of clinical evidence that supports the continued adoption of Focal One as a frontline treatment for localized prostate cancer. The final results from the groundbreaking, prospective HIFI study were presented at this year’s

Forward-Looking Statements

Forward-Looking Statements In addition to historical information, this press release contains forward-looking statements within the meaning of applicable federal securities laws, including Section 27A of the U.S. Securities Act of 1933 (the “Securities Act”) or Section 21E of the U.S. Securities Exchange Act of 1934, which may be identified by words such as “believe,” “can,” “contemplate,” “could,” “plan,” “intend,” “is designed to,” “may,” “might,” “potential,” “objective,” “target,” “project,” “predict,” “forecast,” “ambition,” “guideline,” “should,” “will,” “estimate,” “expect” and “anticipate,” or the negative of these and similar expressions, which reflect our views about future events and financial performance. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others, the clinical status and market acceptance of our HIFU devices and the continued market potential for our lithotripsy and distribution divisions, as well as risks associated with the current worldwide inflationary environment, the uncertain worldwide economic, political and financial environment, geopolitical instability, climate change and pandemics like the COVID 19 pandemic, or other public health crises, and their related impact on our business operations, including their impacts across our businesses or d

Forward-looking statements speak only as of the

Forward-looking statements speak only as of the date they are made. Other than required by law, we do not undertake any obligation to update them in light of new information or future developments. These forward-looking statements are based upon information, assumptions and estimates available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete. Company Contact Blandine Confort Investor Relations / Legal Affairs EDAP TMS SA +33 4 72 15 31 50 bconfort@edap-tms.com Investor Contact John Fraunces LifeSci Advisors, LLC (917) 355-2395 jfraunces@lifesciadvisors.com 5 EDAP TMS S.A. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Amounts in thousands of Euros and U.S. Dollars, except per share data) Three Months Ended Three Months Ended June 30, June 30, June 30, June 30, 2024 2023 2024 2023 Euros Euros $US $US Sales of medical equipment 11,118 9,804 11,948 10,657 Net sales of RPP and leases 1,886 1,751 2,027 1,903 Sales of spare parts, supplies and services 2,787 2,724 2,995 2,961 TOTAL NET SALES 15,791 14,278 16,970 15,522 Other revenues — — — — TOTAL REVENUES 15,791 14,278 16,970 15,522 Cost of sales (9,872 ) (8,623 ) (10,609 ) (9,374 ) GROSS PROFIT 5,919 5,655 6,361 6,148 Research & development expenses (2,077 ) (1,677 ) (2,232 ) (1,823 ) Selling, general & administrative expenses (9,989 ) (8,203 ) (10,736 ) (8,917 ) Total operating expenses (12,066 ) (9,880 ) (12,967 ) (10,740 ) OPERATING PROFIT (LOSS) (6,147 ) (4,225 ) (6,606 ) (4,592 ) Interest (expense) income, net 190 255 204 278 Currency exchange gains (loss), net (49 ) (508 ) (52 ) (552 ) LOSS BEFORE INCOME TAXES (6,005 ) (4,477 ) (6,454 ) (4,867 ) Income tax (expense) credit (127 ) (221 ) (136 ) (240 ) NET LOSS (6,132 ) (4

View Full Filing

View this 6-K filing on SEC EDGAR